Investment Thesis

Moderna, Inc. is a BUY at current prices of $50.03. The market appears to underestimate the durability of Moderna’s mRNA platform and its potential to expand beyond COVID-19 vaccines into a wide array of infectious diseases and oncology. With a robust pipeline and strategic partnerships, the company is positioned to capitalize on significant growth opportunities, which are not fully reflected in its current market capitalization of $19.76 billion.

Competitive Moat

characterized by its intangible assets, particularly its intellectual property surrounding mRNA technology. This technology, along with a substantial clinical pipeline, gives Moderna a unique position in the biotechnology sector that is difficult for competitors to replicate. The moat is expected to remain durable over the next 5-10 years, especially as the company continues to innovate and expand its applications. The primary competitive threats include established pharmaceutical firms like Pfizer and emerging biotech companies developing alternative vaccine technologies.

Growth Engine

Future revenue growth for Moderna is expected to stem from its expansive total addressable market (TAM) in infectious diseases, oncology, and rare diseases, projected to exceed $100 billion annually. With the successful rollout of its COVID-19 vaccine, the company has demonstrated pricing power and brand recognition that can be leveraged for new products. Organic growth will be driven by continued advancements in its pipeline, including respiratory and cancer vaccines, while strategic partnerships may enable faster market penetration in international markets. Currently, Moderna is gaining market share in the vaccine sector, particularly as booster shots and new mRNA applications become more prevalent.